Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 66Neoplasms 49Stomach Neoplasms 45Colorectal Neoplasms 42Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 30Uterine Cervical Neoplasms 28Rectal Neoplasms 28Carcinoma, Hepatocellular 25Prostatic Neoplasms 24Recurrence 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 18Neoplasm Metastasis 16Colonic Neoplasms 16Esophageal Neoplasms 15Urinary Bladder Neoplasms 14Thyroid Neoplasms 14Pancreatic Neoplasms 14Nasopharyngeal Carcinoma 14Leukemia, Myeloid, Acute 13Head and Neck Neoplasms 13Small Cell Lung Carcinoma 11Papillomavirus Infections 11Multiple Myeloma 11Motor Activity 11Melanoma 11Lymphoma 11Sarcoma 10Lymphoma, Non-Hodgkin 10

Interventions

lenvatinib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Advanced Primary Liver Cancer × Clear all
NCT05411757 2022-06-09

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Shandong Public Health Clinical Center

Phase EARLY_PHASE1 Unknown
12 enrolled

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡